| 3.35 0.09 (2.76%) | 04-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.13 | 1-year : | 4.76 |
| Resists | First : | 3.53 | Second : | 4.07 |
| Pivot price | 3.4  |
|||
| Supports | First : | 2.66 | Second : | 2.21 |
| MAs | MA(5) : | 3.4  |
MA(20) : | 3.32 |
| MA(100) : | 3.96 |
MA(250) : | 3.66 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 26.2 |
D(3) : | 35.1 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 6.55 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SANA ] has closed above bottom band by 43.3%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.48 - 3.52 | 3.52 - 3.54 |
| Low: | 3.12 - 3.16 | 3.16 - 3.19 |
| Close: | 3.21 - 3.28 | 3.28 - 3.32 |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Mon, 27 Apr 2026
Sana Biotechnology to present preclinical CAR-T data at May meeting - Investing.com
Mon, 27 Apr 2026
Sana Biotechnology abstract accepted for presentation at ASGCT - Investing.com
Mon, 27 Apr 2026
Sana Biotech surges as Eric Jackson calls it a 100-bagger - MSN
Fri, 24 Apr 2026
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 267 (M) |
| Shares Float | 177 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 75.2 (%) |
| Shares Short | 39,380 (K) |
| Shares Short P.Month | 35,830 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -118.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -144 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -3.49 |
| PEG Ratio | 0 |
| Price to Book value | 5.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|